← back to search

Ji‐Feng Feng

Chinese Academy of Sciences · CN
Area of research
Surgery · Oncology
Research interest
Research interests include Esophageal Cancer Research and Treatment, Inflammatory Biomarkers in Disease Prognosis, Cancer Immunotherapy and Biomarkers, and Gastric Cancer Management and Outcomes.
h-index
23
citations
2,911
works
71
NIH funding
primary concept
Medicine
email

Recent publications

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, <i>EGFR</i> ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
Cancer Communications 2024cited by 19position: middledoi
Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study
Therapeutic Advances in Medical Oncology 2024cited by 5position: middledoi
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
Journal of Clinical Oncology 2024cited by 3position: middledoi
Epidemiology, Prevention, and Treatment of Chemotherapy-Induced Myelosuppression in China: A National Cross-Sectional Study
SSRN Electronic Journal 2024cited by 0position: lastdoi
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Cancer Cell 2022cited by 558position: middledoi
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
JAMA 2021cited by 788position: middledoi
Incidence of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Compliance in Chinese Real Clinical Setting: A Cross-Sectional Multicenter Survey
Research Square 2021cited by 0position: middledoi
Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade.
Journal of Clinical Oncology 2019cited by 24position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rui‐Hua Xu · Henan Medical University2 papers (2019–2024)Hui Luo · Jiangnan University1 papers (2024–2024)Qingyuan Zhang · The Seventh Affiliated Hospital of Sun Yat-sen University1 papers (2024–2024)Qingyuan Zhang · Université Paris Cité1 papers (2019–2019)Zhimin Shao · Shanghai Medical College of Fudan University1 papers (2024–2024)Zhendong Chen · Beijing Computing Center1 papers (2024–2024)Kangsheng Gu · Jiangnan University1 papers (2024–2024)Yiping Zhang · Sun Yat-sen University1 papers (2024–2024)Jiancheng Li · University of North Texas1 papers (2024–2024)Jianhua Shi · Harbin Medical University1 papers (2019–2019) · 1 papers (2024–2024)Jin-hai Tang · Jiangsu Province Hospital1 papers (2024–2024)Qingxia Fan · First Affiliated Hospital of Zhengzhou University1 papers (2024–2024)Xiaojia Wang · Wenzhou Medical University1 papers (2024–2024)Guanghai Dai · Chinese PLA General Hospital1 papers (2019–2019)Quchang Ouyang · Central South University1 papers (2024–2024)Xianglin Yuan · Southwest Jiaotong University1 papers (2019–2019)Shujun Yang · Ningbo University1 papers (2019–2019)Zhichao Fu · South China Agricultural University1 papers (2024–2024)Xichun Hu · Shanghai Medical College of Fudan University1 papers (2019–2019)